BRAF and colorectal carcinoma: In tumors from both mCRC and from curatively resected Stage III CRC in an adjuvant setting (AVANT),40 high MPAS was significantly correlated with poorer outcomes, with a trend for wider separation in patients within the BRAF-mutant subgroup, albeit less statistically significant due to smaller patient number (Fig. 4).